Sun Pharma Share Price, Stock Analysis & Company Profile

Sun Pharmaceutical Industries Limited is the largest pharmaceutical company in India and the fourth-largest specialty generic pharmaceutical company globally. Founded in 1983 by Dilip Shanghvi with just five psychiatry products, the company has grown into a multinational giant with a presence in over 100 countries. 

This page serves as a definitive hub for investors to track the Sun Pharma share price, conduct a detailed Sun Pharmaceutical Industries share price trend analysis, and perform an updated Sun Pharma stock analysis.

About Sun Pharmaceutical Industries Limited

Sun Pharma is headquartered in Mumbai and operates 43 manufacturing facilities across six continents. The company is a leader in high-growth therapeutic areas such as cardiology, psychiatry, neurology, gastroenterology, and diabetology. It is also a global leader in the generic dermatology segment.

The company's success is rooted in its ability to acquire distressed assets and turn them around, with the acquisition of Ranbaxy Laboratories in 2014 being a landmark event that catapulted it to its current market leadership. Sun Pharma is also noted for its research-driven approach, consistently investing in a robust pipeline of complex generics and specialty products.

Sun Pharma Business Model

Sun Pharma operates a vertically integrated business model that spans the entire pharmaceutical value chain, from R&D to Active Pharmaceutical Ingredients (APIs) and finished formulations.

• India Formulations: As the No. 1 player in the Indian market, Sun Pharma holds over 8% market share. It leads in over 12 different medical specialty segments, providing branded generics to millions.

• US Business: The United States is a significant revenue driver. Sun Pharma focuses on the "Specialty" business (dermatology, ophthalmology, and oncology) alongside a large portfolio of generics.

• Emerging Markets & Rest of World: The company has a strong presence in markets like Russia, Romania, South Africa, Brazil, and Mexico.

• Specialty Products: A strategic focus area involving "New Chemical Entities" (NCEs) and complex molecules which offer higher margins and longer life cycles compared to standard generics.

• API Manufacturing: By producing its own APIs, Sun Pharma ensures supply chain security and cost-efficiency for its formulation business.

Sun Pharma IPO and Listing Details

Sun Pharmaceutical Industries has a long and storied history on the Indian stock exchanges, having listed during the early 1990s.

• Listing Year: 1994
• IPO Subscription: The issue was famously oversubscribed by 55 times.
• Face Value at Listing: Rs 10 per share
• Current Face Value: Rs 1 per share
• ISIN: INE044A01036
• Listing Exchanges: BSE and NSE
• NSE Symbol: SUNPHARMA
• BSE Scrip Code: 524715

Sun Pharma Corporate Action History

The company has frequently rewarded its shareholders through various corporate actions that have significantly multiplied the value for long-term investors.

Stock Split History

• 2010: The stock was split from a face value of Rs 5 to Rs 1.
• Ex-Date: 25 November 2010
• Ratio: 5:1 (Investors received 5 shares for every 1 share held).

Bonus Share History

Sun Pharma has issued bonus shares multiple times to capitalize its reserves:

• 2013: 1:1 Bonus Issue.
• 2004: 1:1 Bonus Issue.
• 2000: 2:1 Bonus Issue.

Dividend Policy

Sun Pharma maintains a healthy dividend payout ratio, often sharing approximately 30-35% of its profits with shareholders.

• FY 2025-26: Declared an interim dividend of Rs 11 per share (1100%) in February 2026.
• FY 2024-25: Total dividend was Rs 16 per share (split between an interim and final payout).

Investor Resources Available on This Page

On this page, retail investors can access the following updated analysis tools in their respective tables:

• Price Chart: Track the historical movement and technical trends of the Sun Pharma share price. (data delayed by 15 minutes)

• Company Ratios: Analyse key metrics like P/E Ratio, Return on Equity (ROE), and ROCE.

• Quarterly Results: Stay updated with the latest revenue, EBITDA, and net profit figures.

• Balance Sheet: Examine the company’s asset base, reserves, and debt-free status.

• Cash Flow Statement: Review the company's ability to generate cash from operations and its capital expenditure.

• Shareholding Pattern: Monitor stakes held by Promoters, FIIs, and DIIs (Foreign and Domestic Institutions).

• Pros & Cons: A clear analysis of the company's market dominance versus regulatory risks (like USFDA inspections).

• Annual Reports: Download the latest reports and investor presentations for a deep dive into management's future guidance.

Frequently Asked Questions (FAQs)

Q1. What is the latest Sun Pharma share price?
The current market price is displayed at the top of this page. Data from the NSE and BSE is subject to a 15-minute delay.

Q2. Who is the founder of Sun Pharma?
Sun Pharmaceutical Industries was founded in 1983 by Dilip Shanghvi, who remains the Executive Chairman and a major promoter.

Q3. When was the last bonus issue by Sun Pharma?
The last bonus issue was in 2013, where the company issued shares in a 1:1 ratio.

Q4. What is the current face value of Sun Pharma shares?
The face value of each equity share is currently Rs 1.

Q5. Is Sun Pharma a debt-free company?
Yes, Sun Pharma is virtually debt-free on a net basis, maintaining a very strong cash position to fund future acquisitions.

Q6. What is the significance of the Ranbaxy merger?
The 2014-15 merger with Ranbaxy made Sun Pharma the largest pharmaceutical company in India and provided it with a massive global footprint and R&D capability.

Q7. How can I download the latest Sun Pharma Annual Report?
The latest and historical Annual Reports are available for download in the "Reports" or "Documents" section of this page.